网络药理学综合实验验证揭示了奎尔素作为Hedyotis diffusa抗BRCA的关键成分
Queting Chen1, Yuanzhuang Xu2,3, Jianhua Ma1
1Department of Breast Surgery, Affiliated Hospital of Hebei University, Baoding, China.
Chemical biology & drug design
|April 26, 2025
概括
Quercetin 是 Hedyotis diffusa 的一个关键成分,显示出对抗乳腺癌 (BRCA) 的潜力. 这种传统中医 (TCM) 提取物及其活性化合物向参与癌症途径的关键基因.
科学领域:
- 植物化学 植物化学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 花是一种传统中医药 (TCM),具有很长的临床使用历史.
- 它的抗瘤作用是公认的,但针对乳腺癌 (BRCA) 的特定成分和机制需要进一步阐明.
研究的目的:
- 调查Hedyotis diffusa对BRCA的活性成分和分子机制.
- 为了综合分析,将网络药理与实验验证相结合.
主要方法:
- 网络药理学确定素是核心成分,BIRC5,CDK1,FOS和HSP90AA1是关键目标.
- 凯格丰富分析突出了与癌症相关的途径 (例如PI3K-AKT信号传递).
- 在体外实验中验证了昆塞丁对乳腺癌细胞系 (MCF-7,MDA-MB-231) 的作用.
主要成果:
- Quercetin 显著抑制了 MCF-7 和 MDA-MB-231 细胞的增殖,以剂量依赖的方式.
- 奎尔丁治疗导致MCF-7细胞中BIRC5,CDK1和HSP90AA1的表达减少.
- 网络药理学分析预测了参与Hedyotis diffusa抗BRCA活性的关键目标和途径.
结论:
- 奎尔因其抗BRCA作用而被确定为Hedyotis diffusa的关键活性成分.
- 奎瑞会影响乳腺癌细胞中关键基因 (BIRC5,CDK1,HSP90AA1) 的表达.
- 这项研究提供了证据,支持Hedyotis diffusa在治疗BRCA的治疗潜力.
更多相关视频
13:18Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
Published on: March 3, 2023
1.1K
10:39Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module
Published on: June 18, 2015
13.0K
相关概念视频
Cancer Prevention
6.0K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Some...
6.0K
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
